GlassScriptPhysician profile
Thomas D Johnson
NPI 1821096421
$8,997.92
in general payments reported to CMS, 2019-2025
46 companies · $836 in 2025
The $836 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $1,300 · 2021: $1,654 · 2022: $1,187 · 2023: $1,474 · 2024: $1,392 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,081.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $984.91 | 2019-2025 | |
| Abbvie INC. | $933.85 | 2020-2025 | |
| Glaxosmithkline, LLC. | $867.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $472.24 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $392.20 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $384.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $367.49 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $300.94 | 2021-2023 | |
| Esperion Therapeutics, INC. | $280.90 | 2020-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $274.36 | 2023-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $217.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.86 | 2019-2022 | |
| Medtronic, INC. | $200.19 | 2021-2025 | Symplicity G3 |
| Idorsia Pharmaceuticals US INC | $163.35 | 2023-2024 | Quviviq |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.